FDA approved 11 new agents, 30 supplemental indications in cancer in 2019 February 28, 2020Vol.46 No.09By Alexandria Carolan
ODAC: Thumbs up for Eli Lilly’s Cyramza, thumbs down for STEBA’s Tookad February 28, 2020Vol.46 No.09By Paul Goldberg
Funding Opportunities DOD Lung Cancer Research Program to announce funding opportunities for FY20 February 21, 2020Vol.46 No.08
Drugs & Targets FDA grants capmatinib priority review in NSCLC indication February 21, 2020Vol.46 No.08
Drugs & Targets FDA grants Breakthrough Therapy Designation for Astellas’ and Seattle Genetics’ agent Padcev in bladder cancer indication February 21, 2020Vol.46 No.08
Drugs & Targets FDA accepts Valoctocogene Roxaparvovec for Priority Review February 21, 2020Vol.46 No.08
Clinical Roundup Updated CheckMate -025 results demonstrate superior OS, ORR for Opdivo in RCC February 21, 2020Vol.46 No.08
Clinical Roundup Relapse common in weight-loss surgery patients who quit smoking February 21, 2020Vol.46 No.08
Trials & Tribulations Lung cancer: Significant progress leads to record annual decrease in cancer mortality February 21, 2020Vol.46 No.08By Fred R. Hirsch
